About FDA
Total number of new labels (postmarketing) approved in the fiscal year that include clinical pharmacology review on pharmacogenetic, drug-drug interactions and specific population information, etc.
Measure was implemented starting January 2011
Dictionary: These labeling update are considered important to enhance the safe and effective use of drug products even after they are approved. Most times they are based on new knowledge and fulfillment of post-marketing requirement or commitment.
These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Fiscal Year - 2011
Measure was implemented starting January 2011
| Time | Target | Number |
|---|---|---|
| Jan 2011 | N/A | 13 |
| Feb 2011 | N/A | 23 |
| Mar 2011 | N/A | 14 |
| Apr 2011 | N/A | 14 |
| May 2011 | N/A | 14 |
| Jun 2011 | N/A | 27 |
| Jul 2011 | N/A | 14 |
| Aug 2011 | N/A | 12 |
| Sep 2011 | N/A | 13 |
Cumulative number of new labels (postmarketing) approved
Measure was implemented starting January 2011
Dictionary: These labeling update are considered important to enhance the safe and effective use of drug products even after they are approved. Most times they are based on new knowledge and fulfillment of post-marketing requirement or commitment.
Fiscal Year - 2011
Measure was implemented starting January 2011
| Time | Target | Number |
|---|---|---|
| Jan 2011 | N/A | 13 |
| Feb 2011 | N/A | 36 |
| Mar 2011 | N/A | 50 |
| Apr 2011 | N/A | 64 |
| May 2011 | N/A | 78 |
| Jun 2011 | N/A | 105 |
| Jul 2011 | N/A | 119 |
| Aug 2011 | N/A | 131 |
| Sep 2011 | N/A | 144 |
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







